BrainCool AB (publ) receives a new order in Germany, for the product BrainCool™ System

Again, BrainCool receive orders from Germany, now from Städtisches Klinikum Brandenburg, for two products of the BrainCool™ System. The product has been evaluated during the first quarter in competition with two other suppliers of advanced TTM products.

The products will be used on sudden cardiac arrest (“SCA”) patients and delivery and training will take place already in May.

CEO Martin Waleij comments;

We continue to see an increasing interest in our products in Germany. The Covid-19 crisis has indeed led to turbulence for all companies and industries, however, we can see an increased interest in TTM treatment in intensive care. An example is advanced fever treatment for patients with Covid-19 and also in the treatment of SCA (sudden cardiac arrest).

Within the framework of a recently approved EU grant of MEUR 3, we are developing an education and training platform of our TTM products with the German nonprofit intensive care organization IGNITE, which has a focus on neurology (reference 1 - IGNITE). The main focus is neurology, although in consultation with the responsible researchers and doctors, it will also be expanded with information of our products application in SCA, as well as patient cases that have been treated for fever in the new disease Covid 19.

This information is information that BrainCool (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out herein, on May 7, 2020.

Reference 1 - IGNITE (the Initiative of German Neurointensive Trial Engagement), a clinician-led subgroup of the German Society for Neurointensive and Emergency Medicine (“DIVI”) that is focused on research and dissemination of new treatments in the area of emergency stroke treatment.

Information in Swedish only https://spotlightstockmarket.com/sv/market-overview/nyheter//nyhets-artikel?id=57508

For more information

Martin Waleij - CEO                                                               
+46 - 733 -93 70 76                                                                                          
E-mail: martin.waleij@braincool.se                       

About BrainCool AB (publ)

BrainCool AB (publ) is an innovative medical device company that develops, markets, and sells leading medical cooling systems for indications and areas with significant medical benefits within the healthcare sector. The company focuses on two business segments, Brain Cooling and Pain Management. BrainCool AB (publ) is based in Lund, Sweden, and its share is listed on Spotlight Stock Market.

Om oss

BrainCool AB (publ) är ett innovativt medicinteknikföretag som utvecklar, marknadsför och säljer ledande medicinska kylningssystem för indikationer och områden med betydande medicinska mervärden inom sjukvården. Bolaget fokuserar på två affärsområden, Brain Cooling och Pain Management. BrainCool AB (publ) har sitt säte i Lund. Aktien är noterad på Spotlight Stock Market.

Prenumerera

Dokument & länkar